Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • History
    • Organisation
    • New Partnerships
  • Our Science
    • Resolving Inflammation
    • Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
    • Rheumatoid Arthritis
    • Membranous Nephropathy
    • Virus Induced Respiratory Insufficiency
    • Ongoing clinical studies
  • Investors
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committee 2023
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Press Releases

All releases
    • Regulatory
    • Non Regulatory
2019
  • 2023
  • 2022
  • 2021
  • 2020
  • 2018
  • 2017
  • 2016
  • All years
November 11, 2019
Non Regulatory

SynAct receives approval from the Swedish Medical Product Agency and the Swedish Ethical Review Authority regarding the clinical Phase IIa study with AP1189

October 28, 2019
Non Regulatory

Redeye: Adding an indication

October 21, 2019
Regulatory

SynAct conducts private placement and fully guaranteed rights issue with the aim of increasing the commercial value of AP1189

May 2, 2019
Regulatory

SynAct Pharma AB secures bridge loan financing for AP1189

April 17, 2019
Regulatory

SynAct publishes annual report and consolidated accounts for 2018

April 9, 2019
Regulatory

Notice of Annual General Meeting of SynAct Pharma AB

March 29, 2019
Regulatory

SynAct applies for start of phase IIa clinical study in patients with active arthritis

March 21, 2019
Regulatory

Bulletin from the Extraordinary General Meeting at SynAct Pharma AB

February 25, 2019
Non Regulatory

John Haurum and Terje Kalland are proposed as new members of the Board of Directors in SynAct Pharma AB

February 19, 2019
Regulatory

Notice of Extraordinary General Meeting of SynAct Pharma AB (publ)

February 13, 2019
Regulatory

Changes in the Board of Directors of SynAct Pharma

February 11, 2019
Regulatory

Year-end report for the financial year 2018

February 11, 2019
Regulatory

SynAct reported positive phase I results for candidate drug AP1189 and prepared funding for broadened phase II programmes

  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe